Unichem Laboratories and Aurobindo Pharma Recall Their Products in US Market


The Unichem Laboratories and the Aurobindo Pharma have been recalling the different types of the products in the market of the United States, which has been largest market for medicines in the world, because of the manufacturing or production issues.

According to the reports issued by the US FDA, the unit of Aurobindo Pharma based in the United States has been recalling 7,296 containers of the tablets of hypertension drug known as Carvedilol, and the affected lot of the tablets has been containing 6.25 mg Carvedilol tablets, that has been produced in the country of India and has distributed in the United States by the Aurobindo Pharma USA Inc. based in Princeton.

The company has been recalling the lot of the tablets because of the failed specifications of the impurities and degradation, as reported by the US FDA and the company has also initiated the recall across the United States on 15th November 2021.

READ  US FDA Authorized Pfizer’s COVID-19 Vaccine Booster Shots for Children Under Five Years

The Unichem Laboratories has been recalling its 1,284 bottles of the Topiramate tablets, which has been for treating the seizures and also for preventing migraines, and it is also used in the treatment of the Lennox-Gastaut syndrome, which is a rare and severe form of the seizure that starts early during the childhood.

The affected lot of the tablets has also been produced in the plant of Unichem Laboratories based in India and distributed in the United States by the Unichem Pharmaceuticals based in New Jersey, US.